186 related articles for article (PubMed ID: 25664933)
21. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM
Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715
[TBL] [Abstract][Full Text] [Related]
22. Rapid onset of conjunctivitis associated with overdosing of erlotinib.
Sun P; Long J; Chen P; He Q; Gao X; Li S
J Clin Pharm Ther; 2018 Apr; 43(2):296-298. PubMed ID: 29069525
[TBL] [Abstract][Full Text] [Related]
23. Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.
Fiala O; Hosek P; Pesek M; Finek J; Racek J; Stehlik P; Sorejs O; Minarik M; Benesova L; Celer A; Nemcova I; Kucera R; Topolcan O
Anticancer Res; 2017 Nov; 37(11):6469-6476. PubMed ID: 29061834
[TBL] [Abstract][Full Text] [Related]
24. An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.
Szutowicz-Zielińska E; Konopa K; Kowalczyk A; Suszko-Każarnowicz M; Duchnowska R; Szczęsna A; Ratajska M; Sowa A; Limon J; Biernat W; Burzykowski T; Jassem J; Dziadziuszko R
Oncotarget; 2017 Mar; 8(10):17270-17278. PubMed ID: 27924059
[TBL] [Abstract][Full Text] [Related]
25. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Burotto M; Manasanch EE; Wilkerson J; Fojo T
Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
[TBL] [Abstract][Full Text] [Related]
26. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
27. Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Curr Med Res Opin; 2015 Jan; 31(1):25-33. PubMed ID: 25329826
[TBL] [Abstract][Full Text] [Related]
28. Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
Abdel-Rahman O; Ahmed H; ElHalawani H
Expert Rev Respir Med; 2016 Feb; 10(2):223-34. PubMed ID: 26558417
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer.
Minemura H; Yokouchi H; Azuma K; Hirai K; Sekine S; Oshima K; Kanazawa K; Tanino Y; Inokoshi Y; Ishii T; Katsuura Y; Oishi A; Ishida T; Munakata M
BMC Res Notes; 2015 Jun; 8():220. PubMed ID: 26043909
[TBL] [Abstract][Full Text] [Related]
30. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
Bigot F; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Tlemsani C; Chapron J; Huillard O; Cessot A; Vidal M; Alexandre J; Blanchet B; Goldwasser F
Invest New Drugs; 2017 Apr; 35(2):242-246. PubMed ID: 27796680
[TBL] [Abstract][Full Text] [Related]
31. Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.
Aw DC; Tan EH; Chin TM; Lim HL; Lee HY; Soo RA
Asia Pac J Clin Oncol; 2018 Feb; 14(1):23-31. PubMed ID: 28464435
[TBL] [Abstract][Full Text] [Related]
32. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
Spigel DR; Edelman MJ; O'Byrne K; Paz-Ares L; Mocci S; Phan S; Shames DS; Smith D; Yu W; Paton VE; Mok T
J Clin Oncol; 2017 Feb; 35(4):412-420. PubMed ID: 27937096
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Zhang Y; Zhang Z; Huang X; Kang S; Chen G; Wu M; Miao S; Huang Y; Zhao H; Zhang L
Clin Lung Cancer; 2017 Sep; 18(5):e333-e340. PubMed ID: 28462807
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Kelly K; Altorki NK; Eberhardt WE; O'Brien ME; Spigel DR; Crinò L; Tsai CM; Kim JH; Cho EK; Hoffman PC; Orlov SV; Serwatowski P; Wang J; Foley MA; Horan JD; Shepherd FA
J Clin Oncol; 2015 Dec; 33(34):4007-14. PubMed ID: 26324372
[TBL] [Abstract][Full Text] [Related]
35. Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).
Faehling M; Achenbach J; Staib P; Steffen U; Tessen HW; Gaillard VE; Brugger W
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1375-1383. PubMed ID: 29687154
[TBL] [Abstract][Full Text] [Related]
36. Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review.
Gass-Jégu F; Gschwend A; Gairard-Dory AC; Mennecier B; Tebacher-Alt M; Gourieux B; Quoix É
Lung Cancer; 2016 Sep; 99():76-8. PubMed ID: 27565918
[TBL] [Abstract][Full Text] [Related]
37. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
39. Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.
Monnet I; Audigier-Valette C; Girard N; Vergnenègre A; Molinier O; Souquet PJ; Blanchon F; Bonnetain F; Taguieva-Pioger N; Lamour C; Wislez M
Lung Cancer; 2016 Aug; 98():84-90. PubMed ID: 27393512
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Lee CK; Davies L; Wu YL; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu YK; Gralla RJ; Gebski V; Mok T; Yang JC
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
